Page 78 - Read Online

Page 12 of 15 Miliotis et al. J Cancer Metastasis Treat 2020;6:13 I http://dx.doi.org/10.20517/2394-4722.2020.12

Hematol 2000;34:27-53.
12. Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, et al. Gastric carcinoma: monoclonal epithelial malignant cells expressing
Epstein-Barr virus latent infection protein. Proc Natl Acad Sci U S A 1994;91:9131-5.
13. Ribeiro J, Oliveira A, Malta M, Oliveira C, Silva F, et al. Clinical and pathological characterization of Epstein-Barr virus-associated
gastric carcinomas in Portugal. World J Gastroenterol 2017;23:7292-302.
14. Oh ST, Seo JS, Moon UY, Kang KH, Shin DJ, et al. A naturally derived gastric cancer cell line shows latency I Epstein-Barr virus
infection closely resembling EBV-associated gastric cancer. Virology 2004;320:330-6.
15. Nogueira C, Mota M, Gradiz R, Cipriano MA, Caramelo F, et al. Prevalence and characteristics of Epstein-Barr virus-associated gastric
carcinomas in Portugal. Infect Agent Cancer 2017;12:41.
16. Fukayama M, Hayashi Y, Iwasaki Y, Chong J, Ooba T, et al. Epstein-Barr virus-associated gastric carcinoma and Epstein-Barr virus
infection of the stomach. Lab Invest 1994;71:73-81.
17. Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, et al. Outlooks on Epstein-Barr virus associated gastric cancer. Cancer
Treat Rev 2018;66:15-22.
18. Derks S, Liao X, Chiaravalli AM, Xu X, Camargo MC, et al. Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancers.
Oncotarget 2016;7:32925-32.
19. Salmaninejad A, Valilou SF, Shabgah AG, Aslani S, Alimardani M, et al. PD-1/PD-L1 pathway: Basic biology and role in cancer
immunotherapy. J Cell Physiol 2019;234:16824-37.
20. Cao S, Wylie KM, Wyczalkowski MA, Karpova A, Ley J, et al. Dynamic host immune response in virus-associated cancers. Commun
Biol 2019;2:109.
21. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated
advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol 2018;4:e180013.
22. Fashoyin-Aje L, Donoghue M, Chen H, He K, Veeraraghavan J, et al. FDA approval summary: pembrolizumab for recurrent locally
advanced or metastatic gastric or gastroesophageal junction adenocarcinoma expressing PD-L1. Oncologist 2019;24:103-9.
23. Ma LJ, Feng FL, Dong LQ, Zhang Z, Duan M, et al. Clinical significance of PD-1/PD-Ls gene amplification and overexpression in
patients with hepatocellular carcinoma. Theranostics 2018;8:5690-702.
24. Brar G, Shah MA. The role of pembrolizumab in the treatment of PD-L1 expressing gastric and gastroesophageal junction
adenocarcinoma. Therap Adv Gastroenterol 2019;12:1756284819869767.
25. Rimm DL, Han G, Taube JM, Yi ES, Bridge JA, et al. A prospective, multi-institutional, pathologist-based assessment of 4
immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer. JAMA Oncol 2017;3:1051-8.
26. Cho J, Chang YH, Heo YJ, Kim S, Kim NK, et al. Four distinct immune microenvironment subtypes in gastric adenocarcinoma with
special reference to microsatellite instability. ESMO Open 2018;3:e000326.
27. Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high
solid tumors. Clin Cancer Res 2019;25:3753-8.
28. Hislop AD, Annels NE, Gudgeon NH, Leese AM, Rickinson AB. Epitope-specific evolution of human CD8(+) T cell responses from
primary to persistent phases of Epstein-Barr virus infection. J Exp Med 2002;195:893-905.
29. Borozan I, Zapatka M, Frappier L, Ferretti V. Analysis of Epstein-Barr virus genomes and expression profiles in gastric adenocarcinoma.
J Virol 2018;92:e01239-17.
30. Song H, Lim Y, Im H, Bae JM, Kang GH, et al. Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB
(Life cycle of Epstein-Barr virus). Sci Rep 2019;9:3465.
31. Strong MJ, Xu G, Coco J, Baribault C, Vinay DS, et al. Differences in gastric carcinoma microenvironment stratify according to EBV
infection intensity: implications for possible immune adjuvant therapy. PLoS Pathog 2013;9:e1003341.
32. Camargo MC, Kim KM, Matsuo K, Torres J, Liao LM, et al. Circulating antibodies against Epstein-Barr virus (EBV) and p53 in EBV-
positive and -negative gastric cancer. Cancer Epidemiol Biomarkers Prev 2020;29:414-9.
33. Yi K, Ju YS. Patterns and mechanisms of structural variations in human cancer. Exp Mol Med 2018;50:98.
34. Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronné L, et al. Frequent structural variations involving programmed death ligands in
Epstein-Barr virus-associated lymphomas. Leukemia 2019;33:1687-99.
35. Saito R, Abe H, Kunita A, Yamashita H, Seto Y, et al. Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+
immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications. Mod Pathol 2017;30:427-39.
36. Wang Y, Wenzl K, Manske MK, Asmann YW, Sarangi V, et al. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a
unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J 2019;9:73.
37. Kataoka K, Shiraishi Y, Takeda Y, Sakata S, Matsumoto M, et al. Aberrant PD-L1 expression through 3’-UTR disruption in multiple
cancers. Nature 2016;534:402-6.
38. Xu M, Zhang WL, Zhu Q, Zhang S, Yao YY, et al. Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in
Epstein-Barr virus associated malignancies. Theranostics 2019;9:1115-24.
39. Mayr C. Regulation by 3’-untranslated regions. Annu Rev Genet 2017;51:171-94.
40. Nomizo T, Ozasa H, Tsuji T, Funazo T, Yasuda Y, et al. Clinical impact of single nucleotide polymorphism in PD-L1 on response to
nivolumab for advanced non-small-cell lung cancer patients. Sci Rep 2017;7:45124.
41. Yeo MK, Choi SY, Seong IO, Suh KS, Kim JM, et al. Association of PD-L1 expression and PD-L1 gene polymorphism with poor
prognosis in lung adenocarcinoma and squamous cell carcinoma. Hum Pathol 2017;68:103-11.
42. Lee SY, Jung DK, Choi JE, Jin CC, Hong MJ, et al. Functional polymorphisms in PD-L1 gene are associated with the prognosis of